K2 Principal Fund L.P. Has $1.84 Million Holdings in Solid Biosciences Inc. (NASDAQ:SLDB)

K2 Principal Fund L.P. cut its holdings in Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) by 93.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 342,271 shares of the company’s stock after selling 5,218,965 shares during the period. K2 Principal Fund L.P. owned about 4.55% of Solid Biosciences worth $1,841,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Prudential Financial Inc. acquired a new position in Solid Biosciences during the second quarter worth $28,000. Atria Wealth Solutions Inc. acquired a new position in Solid Biosciences during the second quarter worth $33,000. Mirabella Financial Services LLP acquired a new position in Solid Biosciences during the first quarter worth $78,000. Goldman Sachs Group Inc. increased its holdings in Solid Biosciences by 8.7% during the second quarter. Goldman Sachs Group Inc. now owns 383,022 shares of the company’s stock worth $236,000 after buying an additional 30,612 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in Solid Biosciences by 582.0% during the first quarter. XTX Topco Ltd now owns 197,756 shares of the company’s stock worth $237,000 after buying an additional 168,759 shares during the last quarter.

Solid Biosciences Stock Up 2.2 %

SLDB traded up $0.13 during trading on Friday, reaching $6.13. 2,742 shares of the stock were exchanged, compared to its average volume of 31,678. Solid Biosciences Inc. has a twelve month low of $3.40 and a twelve month high of $14.25. The stock’s 50 day moving average price is $5.07 and its two-hundred day moving average price is $5.94. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.39 and a quick ratio of 9.39.

Solid Biosciences (NASDAQ:SLDB – Get Rating) last issued its quarterly earnings data on Thursday, March 23rd. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($2.70) by $2.02. Equities analysts forecast that Solid Biosciences Inc. will post -5.39 EPS for the current fiscal year.

Solid Biosciences Profile

(Get Rating)

Solid Biosciences, Inc is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.